iOnctura announces publication of pioneering research describing the unique biological features of roginolisib
March 16, 2023Business Services
Geneva, Switzerland and Amsterdam, The Netherlands, 16 March – iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients …
Great Ormand Street Hospital enters commercial agreement with Leucid Bio
March 16, 2023Medical Communications
Leucid Bio and Great Ormand Street Hospital NHS Foundation Trust (GOSH) have entered a commercial agreement to manufacture Leucid’s lead …
The Association of the British Pharmaceutical Industry suspends Novo Nordisk for two years
March 16, 2023Sales and Marketing
The Association of the British Pharmaceutical Industry (ABPI) has suspended Danish pharmaceutical company Novo Nordisk after “serious breaches” of the …
Seamless Therapeutics launches with $12.5m in financing
March 16, 2023Research and Development
Seamless Therapeutics, a biotech focusing on the therapeutic potential of gene therapies, has announced it received $12.5m (€11.8m) in seed …
Bristol Myers Squibb works with SpaceX to study biomanufacturing in space
March 16, 2023Medical Communications
It was announced last week that the SpaceX Dragon spacecraft will make its journey to the International Space Station (ISS) …
PHARMANOVIA ENTERS INTO AN EXCLUSIVE LICENSING AGREEMENT WITH AETERNA ZENTARIS FOR THE FIRST AND ONLY ORALLY ADMINISTERED APPROVED MEDICINE FOR THE DIAGNOSIS OF GROWTH HORMONE DEFICIENCY IN ADULTS
March 16, 2023Business Services
BASILDON, UK, 16 MARCH 2023 Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the …
Zolgensma®▼ (onasemnogene abeparvovec) receives NICE final draft guidance in presymptomatic babies up to 12 months with spinal muscular atrophy (SMA)
March 16, 2023Business Services
London, UK, 16th March 2023 – Novartis Gene Therapies has confirmed that the National Institute for Health and Care Excellence …
Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology
March 16, 2023Business Services
Boston, Massachusetts, March 16th, 2023 – Aldena Therapeutics Inc. (Aldena) a private biotech company pioneering siRNA-based therapies for dermatological indications, …
Cough medicines containing pholcodine withdrawn across UK
March 15, 2023Medical Communications
Some cough syrups being sold behind the counter at pharmacies are being withdrawn due to safety concerns surrounding potential allergies …
Novo Nordisk to cut insulin prices by up to 75% in 2024
March 15, 2023Sales and Marketing
Danish pharmaceutical company Novo Nordisk has announced that it will cut its prices for insulin products by up to 75%, …
FDA amends EUA of Pfizer-BioNTech COVID-19 vaccine for paediatric use
March 15, 2023Medical Communications
Yesterday, the FDA announced that it has amended the Emergency Use Authorization (EUA) for the Pfizer-BioNTech bivalent COVID-19 Vaccine. The …
BlueRock Therapeutics collaboration over Parkinson’s disease digital health technology
March 15, 2023Medical Communications
Clinical stage biopharmaceutical company BlueRock Therapeutics has announced a collaboration with Rune Labs and Emerald Innovations. It will look at …
DelSiTech Awarded a Grant to Develop Controlled and Sustained Release Injectables for Prophylactic HIV Vaccine
March 15, 2023Business Services
Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that …
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
March 14, 2023Business Services
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 14, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further …
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
March 14, 2023Business Services
AMSTERDAM, NETHERLANDS, 14 March 2023, Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the …
Acesion Pharma announces positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint achieved
March 14, 2023Business Services
14 March 2023, Copenhagen, Denmark – Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (“AF”), the …
EP0042 receives Orphan Drug Designation from the US Food and Drug Administration
March 14, 2023Business Services
Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an …
Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases
March 14, 2023Business Services
Aarhus, Denmark March 14th, 2023: Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from …
Newron announces 2022 financial results and provides outlook for 2023
March 14, 2023Business Services
Milan, Italy, March 14, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company …
Latest content
FibroFind appoints Lee Borthwick as CEO
